The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Hormone therapy versus chemotherapy as first-line treatment for estrogen receptor-positive metastatic breast cancer (MBC) patients.
T. Y. Chang
No relevant relationships to disclose
C. Lin
No relevant relationships to disclose
Y. Lu
No relevant relationships to disclose
S. H. Kuo
No relevant relationships to disclose
S. Huang
No relevant relationships to disclose
C. Huang
No relevant relationships to disclose
A. Cheng
No relevant relationships to disclose